1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331:365-376.
2. Wolfe RA, Ashby VB, Milfort EL, et al. Comparison of morta¬lity in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
N Engl J Med 1999;341:1725-1730.
3. Rubin RH. Infectious disease complications of renal trans¬plantation. Kidney Int 1993;44:221-236.
4. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004;66:383-389.
5. Saeian K, Franco J, Komorowski RA, Adams MB. Hepatocel-lular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: A case series. Liver Transpl Surg 2003;5:46-49.
6. Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease af¬ter transplantation. Transplantation 1996;61:71-76.
7. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplanta-tion lymphoproliferative disorders. Arch Intern Med
2003;163:1997-2004.
8. Penn I. Why do immunosuppressed patients develop cancer? In: Pimentel E (Eds), Critical Reviews in Oncogenesis. CRC,
Boca Raton 1989; p: 27-29.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
117
0 Malignancy After Renal Transplantation: A Single-Center Experience
9. Ducloux D, Carron PL, Rebibou JM, et al. CD4 lymphocyto-penia as a risk factor for skin cancers in renal transplant re¬cipients. Transplantation 1998;65:1270-1272.
10. Opelz G, Henderson R. Incidence of non-Hodgkin lympho-ma in kidney and heart transplant recipients. Lancet
1993;342:1514-1516.
11. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the
International Society for Heart and Lung transplantation: twenty-second official adult heart transplant report—2005. J
Heart Lung Transplant 2005;24:945-955.
12. Penn I. Malignant melanoma in organ allograft recipients.
Transplantation 1996;61:274-278.
13. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Re¬gistry Donors with a history of cancer. Transplantation
2000;70:1747-1751.
14. Cheung AN, Chan AC, Chung LP, et al. Post-transplantation lymphoproliferative disorder of donor origin in a sex-mis¬matched renal allograft as proven by chromosome in situ
hybridization. Mod Pathol 1998;11:99-102.
15. Denton MD, Magee CC, Ovuvorie C, et al. Prevalence of re¬nal cell carcinoma in patients with ESRD pre-transplantatiton: a pathologic analysis. Kidney Int 2002;61:2201-2209.
16. Penn I. De novo malignances in pediatric organ transplant recipients. Pediatr Transplant 1998;2:56-63.
17. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tu¬mors posttransplantation: a retrospective analysis of 28 years experience at a single centre. Transplant Proc 1997;29: 828¬830.
18. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epitheli¬al cutaneous lesions developing after kidney and heart trans¬plantation. J Am Acad Dermatol 1995;33:222-229.
19. Pedotti P, Cardillo M, Rossini G, Arcuri V, et al. Incidence of cancer after kidney transplant: Results from the North Italy transplant program. Transplantation 2003;76: 1448-1451.
20. Cooper SM, Wojnarowska F. The accuracy of clinical diagno¬sis of suspected premalignant and malignant skin lesions in re¬nal transplant recipients. Clin Exp Dermatol 2002;27:436-438.
21. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003; 63:522-533.
22. Mathew T, Kreis H, Friend P. Two-year incidence of malig¬nancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004;18:446-449.
23. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversi¬on to sirolimus: a successful treatment for posttransplantati-on Kaposi's sarcoma. Transplantation 2004; 77:760-762.
24. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med
2005;352:1371-1373.
25. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosup-pression with the monoclonal antibody OKT3 in cardiac-
transplant recipients. N Engl J Med 1990;323:1723-1728.
26. Duman S, Toz H, Aşcı G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppres-
sion. Nephrol Dial Transplant 2002;17:892-896.
27. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systematic retinoid in combination with topical tre-tinoin fort he treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Trans¬plantation 1995;59:714-719.
28. Adami J, Gabel H, Lindelof B, et al. Cancer risk following or¬gan transplantation: a nationwide cohort study in Sweden. Br
J Cancer 2003;89:1221-7.
29. Penn I. Cancers complicating organ transplantation. N Engl J
Med 1990;323:1767-9.
30. Cockfield SM. Identifying the patient at risk for post-trans¬plant lymphoproliferative disorder. Transpl Infect Dis
2001;3.70-78.
31. Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after re¬nal transplantation varies with time: An analysis of the United States Renal Data System. Transplantation 2006;81:175-180.
32. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med
1996;154:1712-1717.
33. Moosa MR. Kaposi's sarcoma in kidney transplant recipients: a 23-year experience. QJM 2005;98:205-214.
34. Buell JF, Gross TG, Woodle ES. Malignancy after transplanta¬tion. Transplantation 2005;80:S254-264.
35. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-can¬cer effects of immunosuppressive agents used in organ trans¬plantation. Transplantation 2004;77: 1777-1782.
36. Opelz G, Döhler B. Lymphomas after solid organ transplan¬tation: a collaborative transplant study report. Am J Trans¬plant 2004;4:222-230.
37. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in im-munosuppression as initial therapy for posttransplant lymphoproliferative disorder : Analysis of prognostic variab¬les and long-term follow-up of 42 adult patients. Transplan¬tation 2001;71:1076-1088.
38. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing un¬der cyclosporin-steroid therapy. Lancet 1984;1:583-587.
39. Rees L, Thomas A, Amlot PL. Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduc¬tion of immunosuppression. Lancet 1998;352:78-91.
40. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemothe¬rapy for Epstein-Barr virus-posivite post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-6488.
41. Schoch OD, Boehler A, Speich R, Nestle FO. Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation. Transplantation l999;68:1056-1058.
42. Pham PTT, Wilkinson AH, Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kid¬ney transplant recipient with posttransplant lymphoprolifera-tive disease. Transplant Proc 2002;34:1178-1181.
Thank you for copying data from http://www.arastirmax.com